HC Wainwright Expects Weaker Earnings for Connect Biopharma

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings estimates for shares of Connect Biopharma in a research report issued on Friday, October 2nd. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.32) for the quarter, down from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Connect Biopharma (NASDAQ:CNTB) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The company had revenue of $2.75 million during the quarter, compared to the consensus estimate of $0.74 million.

Other research analysts have also recently issued research reports about the company. Canaccord Genuity Group lowered their target price on Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, September 16th. BTIG Research reduced their price target on Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Oppenheimer decreased their price objective on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Weiss Ratings raised Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. Finally, Piper Sandler initiated coverage on shares of Connect Biopharma in a report on Friday, June 26th. They set an “overweight” rating and a $7.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Connect Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $6.14.

Connect Biopharma Stock Up 0.8%

CNTB stock opened at $0.91 on Tuesday. Connect Biopharma has a fifty-two week low of $0.85 and a fifty-two week high of $3.82. The business’s 50 day moving average price is $1.85 and its two-hundred day moving average price is $2.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37. The company has a market capitalization of $57.01 million, a price-to-earnings ratio of -0.76 and a beta of -0.16.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTB. ADAR1 Capital Management LLC purchased a new position in shares of Connect Biopharma in the 1st quarter worth $1,945,000. Knott David M Jr increased its position in Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after acquiring an additional 187,835 shares during the last quarter. Richmond Brothers Inc. bought a new position in Connect Biopharma in the fourth quarter valued at about $489,000. Simplify Asset Management Inc. bought a new position in Connect Biopharma in the first quarter valued at about $135,000. Finally, Bank of America Corp DE purchased a new position in Connect Biopharma in the first quarter worth about $41,000. Institutional investors own 58.72% of the company’s stock.

Trending Headlines about Connect Biopharma

Here are the key news stories impacting Connect Biopharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $1.17 from $1.19, increased its FY2027 forecast to a loss of $0.67 from $1.03, and improved its Q4 2026 estimate to a loss of $0.25 from $0.28. The retained Buy rating provides a positive counterpoint. HC Wainwright Issues Pessimistic Outlook for CNTB Earnings
• Neutral Sentiment: The analyst lowered its Q3 2026 estimate to a loss of $0.32 from $0.30, while forecasting a full-year 2026 loss of $1.17 versus the $1.10 consensus estimate. This suggests near-term results may remain pressured despite some later-year improvements.
• Negative Sentiment: HC Wainwright made substantial reductions to its longer-term forecasts, cutting FY2028 EPS to a loss of $0.94 from $0.81, FY2029 to a loss of $1.10 from $0.50, and FY2030 to a loss of $1.16 from $0.10. The revisions imply weaker expected profitability and could weigh on the stock, particularly as CNTB remains an early-stage biotechnology company with ongoing operating losses.
• Neutral Sentiment: A separate report compared Connect Biopharma with Inhibrx Biosciences but provided no clear new operating, clinical, or financial catalyst for CNTB. Financial Contrast: Connect Biopharma and Inhibrx Biosciences

About Connect Biopharma

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.